[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypoglycaemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypoglycaemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,80,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100633393","developing-a-colonoscopy-preparation-protocol-for-patients-with-diabetes-100633393",false,"NCT07526103","Developing a Colonoscopy Preparation Protocol for Patients With Diabetes","Inclusion Criteria:\n\n1. Patients Age over the age of 18\n2. Able to read and understand the English language\n3. Confirmed diagnosis of diabetes (Type 1 or Type 2)\n\nExclusion Criteria:\n\n1. Patients without diabetes\n2. Patients with prior hospital admission due to hypoglycemic events\n3. Patients who have inflammatory bowel disease\n4. Patients with ileus or bowel obstruction\n5. Patients with history of colorectal resection\n6. Patients receiving combined upper and lower endoscopies\n7. Patients with ascites\n8. Patients with previously documented severe renal impairment\n9. Unable to provide consent\n10. Pregnant or lactating female (females of child-bearing potential will undergo urine pregnancy testing)\n11. Patients who have had a recent myocardial infarction(\\\u003C6months)\n12. Allergy to product ingredients","ALL","18 Years","75 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","Patients with diabetes have less effective colonoscopy preparation when compared to nondiabetic patients. This leads to the possibility of missed polyps, longer procedural time and patient dissatisfaction. Furthermore, the peri-colonoscopy period has been associated with increased risk of hypoglycemic events given the required change in diet and possible changes in antihyperglycemic medication regime, though this area is not well studied.\n\nStudies have found that same day preparation for colonoscopy allowed for comparable bowel visualization to split dosing. Pairing this with a low fiber diet permitted the day prior to colonoscopy, the extent of changes to routine and diet within a patient with diabetes day for colonoscopy preparation is minimized and could reduce risk of side effects and hypoglycemia, while also ensuring adequate bowel preparation.\n\nThis study tests the hypothesis that creating a diabetic specific protocol (permitting a low fibre diet the day prior to colonoscopy and using same day preparation) will result in fewer hypoglycemic events and more adequate quality preparation in comparison to a conventional 2L PEG split day preparation with dietary restrictions in patients with diabetes.",[26,27,28],"Hypoglycaemia","Diabete Mellitus","Colonoscopy (Ambulatory Patients)",[30,31,32],"glucose monitoring","diabetes protocol","bowel preparation","NOT_YET_RECRUITING","2026-04-21",{"date":36,"type":37},"2026-04-24","ACTUAL",{"date":39,"type":20},"2026-06-01",{"date":41,"type":20},"2028-06-01",{"name":43,"class":44},"Queen's University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":45},"100631592","validation-of-remote-photoplethysmography-for-non-invasive-estimation-of-blood-glucose-and-hba1c-100631592","NCT07502690","Validation of Remote Photoplethysmography for Non-Invasive Estimation of Blood Glucose and HbA1c","Validation of Remote Photoplethysmography for Non-Invasive Estimation of Blood Glucose and HbA1c in a Community-Based Population in Jakarta","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Willing to participate and provide informed consent\n3. Able to undergo facial scan and blood examination\n4. Stable clinical condition\n\nExclusion Criteria:\n\n1. Facial conditions interfering with rPPG signal (e.g., wounds, deformities)\n2. Use of facial coverings obstructing camera detection\n3. Inability to remain still during facial scan\n4. Incomplete data or withdrawal from study",true,{"count":55,"type":20},300,"1 Day","OBSERVATIONAL","The goal of this observational study is to evaluate whether a non-invasive facial scan technology using remote photoplethysmography (rPPG) can accurately estimate blood glucose and HbA1c levels in adults living in the community in Jakarta. The study focuses on adults aged 18 years and older, including individuals with or without diabetes.\n\nThe main questions it aims to answer are:\n\n1. Can rPPG-based facial scan estimates of blood glucose and HbA1c match results from standard laboratory blood tests?\n2. How well can rPPG identify individuals with high blood sugar or diabetes risk based on established clinical cut-off values?\n\nResearchers will compare results from the rPPG facial scan with standard laboratory measurements of fasting blood glucose and HbA1c to determine how accurate and reliable the technology is for screening purposes.\n\nParticipants will:\n\n1. Provide basic information such as age, sex, and medical history\n2. Undergo a non-invasive facial scan using a smartphone-based system\n3. Have a blood sample taken to measure fasting blood glucose and HbA1c\n4. Complete all assessments during a single study visit\n\nThis study aims to determine whether rPPG can serve as a simple, non-invasive, and accessible tool for early detection and monitoring of diabetes in community settings.",[60,61,62,26],"Diabetes Mellitus","Hyperglycaemia (Diabetic)","Hyperglycaemia (Non Diabetic)",[64,65,66,67,68,69,70],"remote photoplethysmography","rppg","blood glucose","HbA1c","diabetes mellitus","non-invasive monitoring","digital health screening","2026-04-15",{"date":73,"type":37},"2026-04-20",{"date":75,"type":20},"2026-03-23",{"date":77,"type":20},"2026-12-30",{"name":79,"class":44},"Tarumanagara University",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":15,"minAge":56,"maxAge":16,"enrollmentInfo":86,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":45},"100633948","a-study-of-endocrine-metabolic-and-genetic-risk-factors-of-pediatric-persistent-hypoglycemia-at-sohag-university-hospital-100633948","NCT07533318","A Study of Endocrine, Metabolic, and Genetic Risk Factors of Pediatric Persistent Hypoglycemia at Sohag University Hospital","Inclusion Criteria:\n\n* All patients from birth up to 18 years of life who presented with persistent and recurrent hypoglycemia, will be included in the study Persistent hypoglycemia (PH) is that persist beyond 3 days or Per the AAP guidelines, if it is not possible to maintain a glucose concentration \\>45 mg\u002FdL after 24 hours with using a GIR rate of 5-8 mg\u002Fkg\u002Fmin (5,6) Recurrent hypoglycemia is the occurrence of more than 2 episodes of low blood sugar, often associated with symptomatic neuroglycopenia.\n\nExclusion Criteria:\n\n* Transient hypoglycemia:e.g Neonate:e.g\n\n  1. Infant of a diabetic mother\n  2. Prematurity\n  3. Intra-uterine growth retardation\n  4. Perinatal stress ( infection\u002Fsepsis, asphyxia, hypothermia, and respiratory distress)\n  5. Maternal beta blocker use Infant and Childhood:e.g\n\n  \u003C!-- -->\n\n  1. Malnutrition (marasmus or kwashiorkor)\n  2. Illness ( gastroenteritis, vomiting, or diarrhea leading to inadequate intake )\n  3. Prolonged exercise\u002Ffasting\n  4. Diabetic patient on insulin therapy\n  5. Medications\u002F toxins: accidental ingestion of diabetes medication, alcohol, or aspirin\n  6. Factitious hypoglycemia",{"count":87,"type":20},50,"Glucose is the key metabolic substrate for tissue energy production. In the perinatal period, the mother supplies glucose to the fetus, and for most of the gestational period, the normal lower limit of fetal glucose concentration is around 54 mg\u002Fdl (3 mmol\u002FL)(1). During the first 24-48 hours of life, as normal neonates transition from intrauterine to extrauterine life, their plasma glucose (PG) concentrations are typically lower than later in life (2). Distinguishing between transitional neonatal glucose regulation in normal newborns and hypoglycemia that persists or occurs for the first time beyond the first 3 days of life is important for prompt diagnosis and effective treatment to avoid serious consequences, including seizures and permanent brain injury (2) The definition of hypoglycemia remains controversial in neonates and children. Some approaches define hypoglycemia on the basis of symptoms, others on the PG value. According to the American Academy of Pediatrics (AAP) and Pediatric Endocrine Society (PES), hypoglycemia is diagnosed when plasma glucose is, respectively, \\\u003C47 mg\u002FdL and \\\u003C50 mg\u002FdL in at term newborns during the first 48 h of life. Different threshold values have been proposed for pre-term infants (3,4) .\n\nIn at-term newborns after the first 48 h of life, infants and younger children, hypoglycemia is defined when plasma glucose is \\\u003C50 mg\u002FdL. This threshold value is low enough to avoid false-positive results, but is unlikely to lead to permanent neurological damage. In older children, it is possible to use Whipple's triad characterized by signs and\u002For symptoms of hypoglycemia, reduced plasma glucose concentration and resolution of these signs\u002Fsymptoms after acquisition of normoglycemic status(3,4). Per the AAP guidelines, if it is not possible to maintain a glucose concentration \\>45 mg\u002FdL after 24 hours with using a glucose infusion rate (GIR) rate of 5-8 mg\u002Fkg\u002Fmin, consideration should be given to the possibility of a disorder causing persistent hypoglycemia (5,6) Also, Persistent hypoglycemia (PH) beyond 3 days of life warrants investigation. (7) Blood glucose concentrations are maintained within this range by a complex interplay of hormones that control glucose production and utilization. The key hormones that regulate glucose homeostasis include insulin, glucagon, epinephrine, norepinephrine, cortisol, and growth hormone. Pathological endocrine and metabolic conditions that affect either glucose production or utilization can lead to hypoglycemia (8) The most common causes of hypoglycemia in children are diabetes and idiopathic ketotic hypoglycemia. Hypoglycemia also occurs in other endocrine disorders and inborn errors of metabolism (IEMs). In most cases, hypoglycemia is due to increased usage of glucose (hyperinsulinism, fatty acid oxidation disorders (FAODs), sepsis), decreased nutritional supply (gastroenteritis), or decreased endogenous production of glucose (adrenal insufficiency, IEMs, liver failure) (8). The primary endocrine cause of persistent neonatal hypoglycemia is hyperinsulinism (HI), where dysregulated insulin secretion suppresses ketone production and deprives the brain of alternative fuels. HI can be genetic, such as mutations in the KATP channel genes, or acquired due to perinatal stress factors like intrauterine growth restriction. Hormone deficiencies, including hypopituitarism with cortisol and growth hormone deficiency, can also present with hypoglycemia in the newborn period (4). Metabolic disorders causing hypoglycemia include fatty acid oxidation disorders, which prevent fat breakdown and result in hypoketotic hypoglycemia with potential liver or cardiac involvement. Glycogen storage diseases impair glucose release from glycogen stores and gluconeogenesis, leading to severe fasting hypoglycemia accompanied by elevated lactate and hepatomegaly. Disorders of gluconeogenesis similarly disrupt the liver's ability to convert substrates like alanine and glycerol into glucose (4). Genetic causes of hypoglycemia in children include monogenic defects such as mutations in ABCC8 and KCNJ11 causing congenital hyperinsulinism, as well as genes involved in glycogen storage diseases (e.g., G6PC, PYGL), gluconeogenesis (e.g., FBP1), and hormonal regulation (e.g., GLUD1, HNF4A). Advances in next- generation sequencing have enabled the identification of both common and rare genetic etiologies, improving diagnostic accuracy and personalized management (4).\n\nRetrospective studies suggest the rate of undiagnosed endocrine or metabolic disorders in pediatric patients with recurrent hypoglycemia is as high as 8-28% (9,10) In our study, we will use a stepwise approach to help early and accurate diagnosis of endocrine, metabolic, and suspected genetic causes of persistent hypoglycemiaamong children at Sohag University Hospital.",[26],"2026-04-09",{"date":92,"type":37},"2026-04-16",{"date":71,"type":20},{"date":95,"type":20},"2028-04-15",{"name":97,"class":44},"Sohag University",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":45},"100599750","intermittent-versus-continuous-glucose-monitoring-in-intensive-care-unit-100599750","NCT07088549","Intermittent Versus Continuous Glucose Monitoring in Intensive Care Unit","Effect of Continuous Interstitial Glucose Monitoring on Glycaemic Targets and Clinical Outcomes in Critically Ill","ICONS-ICU","Inclusion Criteria:\n\n* age ≥ 18 years\n* admission to the level 3 ICU\n* two consecutive blood glucose measurements \\> 10.0 mmol\u002FL\n* intravenous insulin therapy\n\nExclusion Criteria:\n\n* expected ICU stay \\\u003C 48 hours\n* pregnancy\n* type 1 diabetes\n* diabetic emergencies (DKA, DAHS)\n* severe skin disease\n* severe neutropenia (\\\u003C 0.5 × 10\\^9\u002FL)\n* severe coagulopathy (thrombocytes \\\u003C 20 × 10\\^9\u002FL)\n* manufacturer-defined conditions (hydroxyurea use, acetaminophen more than 4 g daily)",{"count":107,"type":20},200,[23],"Glucose control is an important part of supportive care for critically ill patients. Achieving optimal glucose control in such situations is challenging due to frequent fluctuations in blood glucose levels. These changes are often difficult to detect because the monitoring procedures are complex and require significant staff involvement, frequent blood draws, and consequent blood loss. Continuous glucose monitoring (CGM) is a simple and minimally invasive technique that has been approved and increasingly used by people with diabetes mellitus. However, its effectiveness in terms of glucose control management and accuracy in conditions with severe organ dysfunction has not been established.\n\nThe goal of this study is to assess the performance of CGM-guided glucose control in comparison to the standard glucose monitoring procedure. Additionally, the accuracy of CGM measurements under critical conditions will be evaluated against the standard of care.",[111,112,26],"Critical Illness","Hyperglycaemia",[114,115],"continuous glucose monitoring","icu","2025-07-19",{"date":118,"type":37},"2025-07-28",{"date":120,"type":20},"2025-07",{"date":122,"type":20},"2026-12",{"name":124,"class":44},"University Medical Centre Ljubljana"]